—
C+
C+ The full Closelook — membership. Open the C+ overview

Rhythm Pharmaceuticals Inc (RYTM) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Rhythm Pharmaceuticals Inc

RYTM in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Rhythm Pharmaceuticals develops treatments for rare genetic forms of obesity linked to faults in the melanocortin-4 receptor pathway that controls hunger. Its approved drug, setmelanotide, treats several of these inherited conditions, and it is testing further MC4R-pathway compounds, including an oral pill and a longer-acting injectable, in patients with related genetic and hypothalamic obesities. It is based in Boston and sells directly to patients diagnosed with these rare conditions rather than the broader obesity market.
Where it sits in the stack
Rhythm sits outside our index build; it belongs to the healthcare and biotechnology sleeve of the diary's universe, alongside other rare-disease drug developers rather than the AI-infrastructure names our indices track.
Who it is priced against
The diary has not set a peer group for it; the comparison the market draws is with Zealand Pharma, another company developing therapies for rare metabolic and obesity-linked conditions.
Why Closelook tracks it
It carries no index seat and no Closelook score, and the diary has not quoted it in any edition; coverage here rests only on its chart reading.
What the diary watches
Whether trial results for the newer MC4R compounds widen the eligible patient population beyond the rare conditions setmelanotide already treats.

Rhythm Pharmaceuticals Inc (RYTM) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 41/100 composite (momentum 51, quality 20, valuation 5) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for RYTM, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: initiation by Wolfe Research, 2026-09-17

The Street on this name

Analyst actions and the latest print for RYTM from the Closelook wires — third-party opinions on the record, not our readings.

  • Initiation Wolfe Research — at Outperform Initiated to Outperform 2026-09-17

1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against RYTM on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What RYTM pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +6.5% in FY2025 67 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Rhythm Pharmaceuticals Inc (RYTM)?

Rhythm Pharmaceuticals Inc trades as RYTM on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is RYTM in a Closelook index?

Not currently — Rhythm Pharmaceuticals Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Rhythm Pharmaceuticals Inc's Closelook composite score?

41 out of 100, with momentum 51, quality 20 and valuation 5 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does RYTM trade against its moving averages?

Mixed moving-average stack: Trades -7.2% vs the 50-day and -0.1% vs the 200-day average, 18.8% below the 52-week high and +33.2% off the 52-week low; a golden cross printed 40 sessions ago. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Rhythm Pharmaceuticals Inc do?

Rhythm Pharmaceuticals develops treatments for rare genetic forms of obesity linked to faults in the melanocortin-4 receptor pathway that controls hunger. Its approved drug, setmelanotide, treats several of these inherited conditions, and it is testing further MC4R-pathway compounds, including an oral pill and a longer-acting injectable, in patients with related genetic and hypothalamic obesities. It is based in Boston and sells directly to patients diagnosed with these rare conditions rather than the broader obesity market. The diary has not set a peer group for it; the comparison the market draws is with Zealand Pharma, another company developing therapies for rare metabolic and obesity-linked conditions.

Where does Rhythm Pharmaceuticals Inc sit in the AI build-out?

Rhythm sits outside our index build; it belongs to the healthcare and biotechnology sleeve of the diary's universe, alongside other rare-disease drug developers rather than the AI-infrastructure names our indices track. It carries no index seat and no Closelook score, and the diary has not quoted it in any edition; coverage here rests only on its chart reading.

Does Rhythm Pharmaceuticals Inc pay a dividend?

No cash distribution shows in Rhythm Pharmaceuticals Inc’s price series over the last three years. The share count rose 6.5% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Rhythm Pharmaceuticals Inc recently?

The most recent analyst action on Rhythm Pharmaceuticals Inc on the Closelook wire is a initiation by Wolfe Research on 2026-09-17 (at Outperform). 1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for RYTM, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.